Back to top

Allogene Therapeutics (ALLO) Gets a Buy from Oppenheimer

Oppenheimer analyst Matthew Biegler reiterated a Buy rating on Allogene Therapeutics yesterday and set a price target of $7.00. Biegler covers the ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Allogene Therapeutics, Inc. (ALLO)